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 Background: The initial systolic blood pressure (SBP) in patients with acute heart 
failure (AHF) can be used as a guide when choosing specific pharmacologic treatments 
by helping identify the underlying type of HF (e.g., HF with preserved ejection fraction).   
Clinical experience and research data from our medical center suggests that AHF with 
elevated SBP may be presenting less frequently than in the past.   This may call into 
question the utility of initial SBP as a clinical guide. The goal of this Master’s Thesis is to 
test the hypothesis that the frequency of AHF patients with a SBP>160mmhg has 
declined over time.  
Methods: This observational study compares data from 4 cohorts of adult patients 
admitted with AHF in central MA. Data were obtained from    a contemporary (2011-
2013) study of patients with AHF as well as from the 1995, 2000, 2006 Worcester Heart 
Failure Study (WHFS) cohorts.   The  Framingham criteria  the diagnostic criterion for 
AHF.   The main outcome was the proportion of patients with AHF with a SBP > 160 
mmHg who presented in each of the 4 study cohorts and was examined by  multivariate 
logistic regression. 
Results:  2,366 patients comprised the study population. The average age was 77 
years, 55% were female, 94% white, and 75% had prior HF.    In 1995 33.6% of AHF 
patients had a SBP >160 mmHg compared to 19.5% in 2011-2013 (p<0.01). 
Multivariate logistic regression demonstrated a reduced odds of patients presenting with 
a SBP>160 mmHg in 2006 (0.64, (0.42-0.96))  and 2011-13  (0.46, (0.28-0.74)).  
Conclusion: The proportion of patients with AHF and an initial SBP >160 mmHg   has 
significantly declined over time. This may warrant a reexamination of the utility of SBP 
to inform diagnosis and treatment in patients with AHF. 
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CHAPTER I 
 
INTRODUCTION 
 
There are more than 5 million Americans who have been diagnosed with heart 
failure (HF), and each year there are greater than 650,000 new cases of HF that occur 
among adult American men and women. 1  The majority of these episodes of acute HF 
(AHF) are cared for in the Emergency Department (ED) setting, resulting in nearly 1 
million ED visits 2 and 1 million hospital admissions annually. 1, 3  Efficiently arriving at 
the diagnosis of AHF and starting appropriate treatment for these high risk patients can 
be challenging in the ED setting for a variety of reasons. These include the limited time 
available for patient evaluation and that there is often little known about the patient’s 
previous medical history. However, several basic clinical parameters available at the 
time of hospital presentation provide information that is useful in diagnosing the 
presence of AHF and guiding treatment. 4-6  Therefore, it is recommended that the initial 
management of patient’s  with suspect AHF  be based on the patient’s clinical profile 
which is, in part , determined by their vital signs at the time of ED presentation. 6, 7  
The vast majority of patients with AHF present to the hospital with either elevated 
or normal blood pressure (BP) as few present in a hypotensive state. 6, 7 These initial 
BPs can be used to classify patients as having either “vascular failure”, with systolic 
blood pressures (SBP’s) ≥160 mmHg, or “cardiac failure”, with SBP’s in the normal 
range (110-159 mmHg). 6, 7 Both vascular and cardiac failure profiles are associated 
with unique clinical features that are useful in guiding the approach to therapy. These 
profiles are also related to the type of left ventricular dysfunction (systolic versus 
diastolic) that the patient may have, 4, 5    and may be used by ED providers to guide 
2 
 
clinical decision making as to the choice of  pharmacologic and other therapies that 
should be employed to relieve patient’s acute symptoms and pulmonary congestion. 
Longitudinal studies have documented that many changes have occurred with 
regard to the clinical characteristics, management, and prognosis of patients with HF  
over the past several  decades including advancing  age, increasing comorbid disease 
burden, increased use of certain medications, and increased short and longer-term 
survival. 8, 9 There have also been several changes in the outpatient management of 
hypertension over time as definitions and targets of therapy have evolved. 10-12 In 
addition, clinical experience and recent unpublished research data from our medical 
center suggests that AHF patients with the vascular-failure profile may be presenting 
less frequently than in the past.  If patient presentations of both AHF and elevated SBP 
are becoming less common than in the past, it may become more difficult to clinically 
distinguish between vascular and cardiac failure patients. Because of the importance 
that SBP plays in making the diagnosis and instituting appropriate management of AHF 
in the ED, the goal of this Master’s Thesis is to test the hypothesis that the frequency of 
AHF presentations in the ED associated with hypertension (SBP>160mmhg) has 
declined over time.  
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CHAPTER 2 
 
STUDY METHODS 
 
This Master’s Thesis compares data collected at the time of hospital 
presentation, specifically SBP, from patients seen in the EDs of 3 teaching hospital in 
central Massachusetts and ultimately admitted to the hospital with AHF. All data for this 
study were  obtained from two separate NIH (NHLBI) sponsored research studies.   The 
first  study is a contemporary (2011-2013), observational investigation of the ED 
treatment of adult patients with AHF that has the overall goal of examining how ED-
based treatment impacts short-term (inpatient) clinical outcomes. (K23HL101991, C. 
Darling PI). The second study is the Worcester Heart Failure Study (WHFS) which was 
a large, multicenter NHLBI funded investigation (R37 HL69874, R. Goldberg PI) based 
in central, MA that studied the clinical characteristics, treatments, and outcomes of adult 
patients admitted with AHF over multiple study years between 1995 and 2006.   Each  
of these studies used the same diagnostic criteria for AHF, namely the   Framingham 
criteria for HF.13 The Framingham criteria was chosen because it has been used in 
several studies, including the WHFS 13-17, and it is relatively straightforward to apply.  
The presence, or absence, of the major and minor  criteria used in the Framingham 
Study  was ascertained in both studies by performing chart reviews of ED and inpatient 
clinical data.      The Framingham criteria included the presence of 2 major criteria (e.g., 
orthopnea, increased jugular venous pressure, and radiological evidence of pulmonary 
edema) or 1 major and 2 minor (e.g., extremity edema, exertional dyspnea, and pleural 
effusion) criteria. 18 The specific approaches used in the identification of patients with 
AHF and collection of pertinent data in each of these studies were as follows: 
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 2.1 Contemporary ED-based Study of AHF 
This NHLBI supported investigation   (K23HL101991) began in September, 2011,  
and enrolled patients over 2 years while they were in one of the ED’s of a two campus 
tertiary care medical center (UMass Memorial University and Memorial campuses). In 
order to study   ED-based clinical treatment of patients with AHF, patients were enrolled 
as soon as possible after arriving in the ED.  Patients with possible AHF were identified 
by trained research staff by using the ED computerized tracking system.   Adults ≥18 
years were screened based on their chief complaint, medical history, and a brief 
consultation with the treating physician regarding clinical exam findings. Enrollment 
proceeded for patients with at least 1 sign (e.g., vascular congestion on chest xray, 
rales on lung exam, peripheral edema) and at least 1 symptom (e.g., dyspnea, 
orthopnea) consistent with the presence of AHF.   For the present study we excluded 
AHF in the setting of acute myocardial infarction, in patients  with cardiogenic shock, 
patients currently on hemodialysis, and those with a systolic BP <95mmHg.  The  latter 
BP cutoff restriction was put in place because it was an exclusion criteria for the main 
research aims of the grant that supported the original study. All data for patients 
subsequently discharged from the ED and who were not admitted to the inpatient 
setting were not used for this study.    
2.1a  Data Collection Activities for the ED-based AHF Study 
Clinical data gathered on these patients was first recorded by trained RA’s on 
individual patient data entry forms and then transcribed into a customized Redcap 
database. Initial clinical data (e.g., vital signs) was obtained in real-time while RA’s were 
present in the ED and subsequent data were gathered by a structured chart review at a 
later time. Demographic data included patient’s   age, sex, and race. Historical data 
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included patient’s medical history, current medications, and social history. Clinical data 
regarding ED care included vital signs on arrival (blood pressure, heart rate, respiratory 
rate, pulse oximetry) and at ED discharge (admission), time of ED arrival and departure 
to the inpatient setting, prehospital use of HF specific medications, respiratory 
treatments, urine output, entry laboratory values (e.g., creatinine, B- type natriuretic 
peptide), and type and timing of ED initiated HF-specific medication treatment. For the 
main variable of interest, SBP, we recorded the first available reading after the patient 
arrived at the hospital. This BP reading was obtained via direct observation of vital signs 
obtained on ED arrival. Specific medications of interest included diuretics and afterload 
reducers (nesiritide, nitroglycerin, ACE-inhibitors).  The results of diagnostic tests in the 
ED and hospital including chest x–rays, echocardiography (when done), were also 
recorded. Other in-hospital data included trends in lab values (e.g, serum creatinine) 
over the initial 24 hours, and inpatient complications (e.g., arrhythmias or myocardial 
infarction (MI).    Within 2 months of hospital discharge, a structured chart review was 
undertaken by trained research staff to obtain information on short-term clinical 
outcomes including inpatient length of stay (LOS), need for ICU admission, 
endotracheal intubation and  inpatient mortality.       
2.2 The Worcester Heart Failure Study (WHFS) 
 
Whereas the contemporary AHF study was conducted at a single medical center 
in Worcester, MA, the WHFS studied adult patients admitted to multiple (n=11) hospitals 
in central Massachusetts with the diagnosis of AHF over multiple  study years including 
1995, 2000, 2002, 2004, and 2006.  For the present study, we restricted this patient 
population to patients admitted to one of 3 teaching hospitals in Worcester, MA (UMass-
Memorial University campus and Memorial campus, and St. Vincent Hospital).  We 
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restricted our population to these medical centers for several reasons. First all 3 are in 
Worcester, are teaching hospitals, and see similar patient populations. Secondly, 
including St. Vincent hospital specifically allowed us to increase the size of our study 
sample to enhance the comparisons between study cohorts. The details of the WHFS 
study methods have been published elsewhere 8, 9, 19-21 but will be briefly reviewed 
below.  
2.2a Data Collection Activities in the WHFS 
Patients with potential AHF were first identified by trained WHFS study staff by 
performing a standardized review of the medical records of patients with primary or 
secondary International Classification of Diseases (ninth Revision)  (ICD-(9)) consistent 
with a possible admission for AHF.  Patients who were discharged with the HF code of 
(428.X) were used as the primary means of identifying cases of AHF occurring in 
residents of central MA. In order not to miss other potential cases of AHF, the medical 
records  of patients with other ICD-9 codes where HF may have occurred were 
reviewed by trained study staff.. These records were identified by the following ICD-9 
codes:  rheumatic HF (398.9) acute cor pulmonale (415), diseases of the endocardium 
(424), cardiomyopathy (425.4), hypertensive heart and renal disease (402 and 404), 
pulmonary heart disease and congestion (416.9 and 514), lung edema (518.4), dyspnea 
and respiratory abnormalities (786), and edema (782.3). All available data in the medical 
records were  then used to determine if AHF was present  based on  the Framingham 
Study criteria. 18 Patients who developed AHF following admission for a different acute 
illness (e.g., myocardial infarction) or after a medical procedure were excluded since the 
WHFS was seeking to study patients admitted primarily for AHF. For comparison with 
the contemporary AHF study, we included only adult (>18 years old) patients evaluated 
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in one or our 3 study ED’s and excluded those on hemodialysis, who developed an 
acute MI, cardiogenic shock,  or who presented with a systolic BP less than 95 mmHg.  
Key data elements for both the contemporary AHF and WHFS studies were 
defined based on whether an abstractor could locate the element in question in the 
medical record. For instance, an incident (first) case of AHF was identified when there 
were no prior hospitalizations for AHF or diagnosis of HF, and no prior treatment of HF.  
The WHFS collected a wide range of detailed data relevant to this Master’s Thesis 
study.  Briefly, data were collected about each patient’s demographic, past medical 
history (e.g., coronary heart disease, hypertension, diabetes), physical exam findings, 
home medications, clinical characteristics (e.g., vital signs on arrival, HF symptoms) 
admission status (e.g., ICU versus floor), and laboratory results (e.g., creatinine, beta-
natriuretic peptide).  Initial SBP was defined as the first available SBP in the medical 
record and was collected from the medical records.  Ejection fraction findings were  
obtained if echocardiography  was carried out  during  the index admission.      
2.3 Comparing blood pressures on patients with AHF over time  
The main goal of this  Master’s Thesis is to compare SBP findings at the time of 
ED presentation in patients admitted with AHF over time in order to gain an 
understanding as to whether AHF presentations accompanied by hypertension have 
declined over the past 15-20 years.  We, therefore, obtained initial SBP readings for the 
WHFS study years of 1995, 2000, and 2006, and from the ED-based AHF study (2011-
2013). Hypertension was defined as a systolic BP >160mmHg based on the upper cut 
point of  AHF BP  categories as defined by the OPTIMIZE-HF registry study, 4 and also 
because this high BP  group would be most likely to fall into the “vascular failure” 
phenotype and be treated with afterload reduction agents in the ED setting. 
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2.4  Data Analysis  
Study Population: A total of 338 patients were available from the contemporary AHF 
study for analysis.   To obtain a comparison sample of historical WHFS subjects from 
our 3 study years (1995, 2000, 2006), we took a 2:1 random sample of all available 
subjects in the WHFS database which  resulted in a total of 676 patients from each 
WHFS study cohort. Differences in the demographic and clinical characteristics of 
patients in each of the 4 study groups were compared by chi-square tests for 
categorical variables  and ANOVA for continuous factors.  
Our primary study endpoint was the percentage of patients presenting to the ED 
with AHF who had a SBP > 160mmHg during each of the years under study. Our 
hypothesis was that the frequency of AHF presentations accompanied by hypertension 
(SBP > 160 mmHg) has declined over time. For the univariate analyses, differences in  
the mean arrival SBP according to study year were  compared by chi square tests of 
statistical significance. In addition,  a multivariate logistic regression analysis was 
performed to examine whether study year was associated with a decrease in 
hypertensive AHF presentations over time at a SBP cut point of 160 mmHg. We set 
1995 as the referent year and  created a multiple logistic regression model by adding 
potential confounders to the analysis which were  based on  clinical relevance and a 
P<0.20 on univariate examination.   We made sure to consider  several other additional 
confounders that have been shown to predict mortality and other clinical outcomes in 
patients with AHF 6, 22-25 including patient’s age, sex, history of HF, renal function, 
diabetes, and coronary heart disease, and the need for mechanical ventilation during 
their ED stay.   Ejection fraction findings were missing in  58% of the study sample  and 
was not controlled for  in the regression model. Similarly BNP level was not collected in 
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the 1995 and 2000 study cohorts and was not incorporated into the regression 
analyses. The Committee for the Protection of Human Subjects in Research at the 
University of Massachusetts Medical School approved both the WHFS as well as the 
contemporary ED-based study. 
 
  
 .    
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CHAPTER III 
 
STUDY RESULTS 
 
Characteristics of the entire study population 
A total of 2,366 individuals admitted with AHF were analyzed in this study. This 
included 3 cohorts of 676 randomly selected patients from the WHFS that were 
admitted each year in 1995, 2000, and 2006, and 338 patients admitted between 2011-
2013 in the ED-based study of AHF. The average age of this  study population was 77 
years, 55% were female, 92 % were white, and 75% had been previously diagnosed 
with HF.  Between 1995 and 2011-13 there were several notable changes in the clinical 
characteristics of patients with AHF. Compared to  patients admitted for AHF in 1995, 
those admitted with AHF  in the more recent study years of 2011-13 were significantly 
more likely to have a number of co-morbid cardiovascular conditions previously 
diagnosed  including hypertension, atrial fibrillation, chronic kidney disease, and 
hyperlipidemia. These patients  were also  more likely to be taking ACE-Inhibitors and 
beta-blockers but less likely to be taking digoxin at the time of presentation than more 
recently hospitalized patients. They also had a shorter length of hospital stay (LOS). 
(Table 3.1)  
Trends in the Characteristics of Patients with SBP>160 mmHg  
Among  patients with AHF and an SBP>160 mmHg,  the average age was 76 
years, 61% were female, and 91% were white. Consistent with the findings in  the entire 
study sample, between 1995 and 2011-13 the characteristics of patients with AHF and a 
presenting SBP>160mmHg also  evolved over time. In more recent study years this 
group of patients had a smaller proportion of  women,  a shorter LOS,  a lower mean 
SBP, and fewer were on digoxin as outpatients. In contrast, these patients had higher 
11 
 
ejection fractions, more preexisting hypertension, kidney disease, and hyperlipidemia, 
and a greater percentage were taking ACE-Inhibitors and beta-blockers as outpatients. 
(Table 3.2)  
Mean SBP and the Frequency of  Elevated  SBP Over Time 
The  SBP at presentation averaged 151 mmHg in 1995 and decreased over time 
to 140 mmHg by 2011-2013 (p<0.01).  In 1995, 33.6% of all AHF patients had a SBP 
>160 mmHg which decreased to 19.5% by 2011-2013 (p<0.01). (Figure 3.1)  The 
distribution of SBP across four BP strata has also changed over time with more recent 
years (after 2006) demonstrating a more balanced distribution of  SBP  than earlier 
years where a greater percentage of patients fell into the higher (>140 and >160) SBP 
strata. (Figure 3.2) 
When compared to patients hospitalized in 1995 (referent year),  the crude odds 
ratios demonstrated that there was a significantly lower odds of patients with AHF 
presenting with SBP>160 in 2000, 2006, and 2011-2013. After adjustment for several 
demographic, medical history, and clinical factors only the 2006 and 2011-13 cohorts 
were found to have significantly reduced odds of presenting with a SBP >160 mmHg.  
(Table 3.3) These findings are consistent with our hypothesis that SBP at the time of 
presentation in patients with AHF has declined over time. 
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Table  3.1 Demographic and Clinical Characteristics of Entire Study Sample 
 Study Year  
 1995 2000 2006 2011-13 p-value 
 Demographics (n=676) (n=676) (n=676)  (n=338)  
Age (mean, yrs) 76.7 76.9 77.6 74.8 <0.01  
Female (%) 57.9 56.7 56.4 41.2 <0.01 
White (%) 95.9 91.4 90.1 89.6 <0.01 
Clinical Characteristics   
   
 
Body mass index (kg/m2) 26.9 27.7 28.0 31.7 <0.01 
Triage Systolic BP (mean, 
mm Hg) 151.4 
146.7 141.3 140.0 <0.01 
Diastolic BP (mean, mm 
Hg) 
81.8 76.3 72.1 75.1 <0.01 
Heart Rate (bpm) 94.4 90.4 87.1 88.1 <0.01 
Respiratory Rate 
(breaths/min) 
26.0 23.9 22.6 22.0 <0.01 
Length of stay (days) 
(mean, SD) 7.24 
5.66 5.47 5.50 <0.01 
Chest XRay with 
pulmonary edema (%) 
61.0 51.3 48.8 66.0   0.57 
Mechanical Ventilation 
(%) 
11.1 6.5 4.1 2.7 <0.01 
Inpatient Death (%) 8.0 5.6 5.8 3.2 <0.01 
Mean EF (%)  40.7 43.2 47.3 44.4   0.51# 
Past Medical and 
Surgical History (%)  
 
Hypertension    64.4 68.1 82.7 89.4 <0.01 
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Table 3.1 Legend: Selected demographic and clinical characteristics of the entire study 
sample.   # - missing data in over 50% of patients, ACE-I= angiotensin converting enzyme- 
inhibitor. 
 
 
 
 
  
Atrial fibrillation   36.7 36.7 45.9 53.9 <0.01 
Diabetes mellitus 39.5 38.2 37.9 52.7 <0.01 
Coronary heart disease 56.7 58.4 58.1 58.3   0.63 
Chronic obstructive 
pulmonary disease 
38.0 34.6 40.1 35.8  0.62 
Stroke 15.8 16.4 14.1 18.6  0.89 
Chronic kidney disease 20.6 22.0 36.5 46.5 <0.01 
Heart failure 24.7 26.6 20.7 28.1  0.57 
Hypercholesterolemia 14.4 24.9 53.3 73.7 <0.01 
 HomeMedications (%) 
    
 
 ACE-Inhibitors 39.1 36.1 39.6 55.9 <0.01 
Beta Blockers 21.3 40.4 64.4 74.9 <0.01 
ACE-I + Beta Blockers 7.0 17.5 28.7 44.4 <0.01 
Calcium Channel Blockers 33.6 24.0 23.8 26.3 <0.01 
Diuretics (any) 70.4 66.7 72.0 77.5 <0.01 
Digoxin 39.9 33.1 18.1 18.3 <0.01 
Laboratory 
    
 
Creatinine 1.46 1.50 1.50 1.55   0.52 
Hematocrit (%) 37.2 36.2 35.3 35.1 <0.01 
14 
 Table 3.2 Demographic and clinical characteristics of patients of patients with a 
SBP>160 mmHg on presentation 
 Study Year  
 1995 2000 2006 2011-13 p-value 
 Demographics (n=227 ) (n=189 ) (n=143 )  (n=66)  
Age (mean, yrs) 76.8 76.4 76.7 73.5  0.25 
Female (%) 66.5 61.4 53.9 54.6 <0.01 
White (%) 96.0 87.3 89.5 90.0       0.09 
Clinical Characteristics       
Body mass index (kg/m2) 27.9 28.6 28.3 33.4 <0.01 
Triage Systolic BP (mean, 
mm Hg) 
188.8 184.7 182.1 182.8 <0.01 
Diastolic BP (mean, mm 
Hg) 
94.9 90.7 85.7 91.5 <0.01 
Heart Rate 95.7 92.8 88.7 89.2   0.02 
Respiratory Rate 26.9 24.6 23.3 22.2 <0.01 
Length of stay (days) 
(mean, SD) 
6.90 5.0 4.9 5.1 <0.01 
% Ejection Fraction (mean) 43.0 46.9 49.0 49.1     0.04** 
Chest XRay with pulmonary 
edema (%) 
66.5 54.0 54.6 71.2   0.59 
Past Medical and Surgical 
History (%) 
     
Hypertension    75.3 77.8 88.1 93.9    <0.01 
Atrial fibrillation   32.6 29.6 30.8 45.5 0.23 
Diabetes mellitus 44.9 42.3 39.9 50 0.96 
Coronary heart disease 55.1 57.1 49.0 54.6 0.36 
Chronic obstructive 
pulmonary disease 
35.2 31.2 34.3 25.8 0.36 
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Table 3.2 Legend: Selected demographic and clinical characteristics of patients of patients with   
                                a SBP>160 mmHg on presentation.              
 ** data missing in 55% of cases 
 
 
 
 
 
 
 
 
 
 
 
Stroke 18.1 12.1 16.8 25.8   0.27 
Chronic kidney disease 19.8 22.8 37.8 42.4 <0.01 
Heart failure 72.3 66.1 72.0 60.6   0.35 
Hyperlipidemia 19.4 25.4 48.3 74.2 <0.01 
Home Medications (%)      
 ACE-Inhibitors 36.1 34.4 39.9 62.1 <0.01 
Beta Blockers 26.9 48.2 62.9 77.3 <0.01 
ACE-I + Beta Blockers 7.5 21.1 29.4 50.0 <0.01 
Digoxin 36.6 26.5 14.0 7.6 <0.01 
Diuretics (any) 64.8 56.6 60.1 69.7       0.81 
Laboratory      
Creatinine, mean (mg/dl) 1.46 1.50 1.50 1.55 0.80 
Hematocrit mean (%) 38.1 36.9 36.2 35.9 0.03 
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Table 3.3 Crude and multivariable adjusted  odds ratios for patients with AHF 
presenting  with a SBP> 160 mmHg 
 
 Crude OR Adjusted OR* 
 19950 1.0 1.0 
2000 0.70 
(0.54-0.90)$ 
0.94 
(0.67-1.31) 
                     2006 0.41 
(0.30-0.55) 
0.64 
(0.42-0.96) 
      2011-13 0.35 
(0.23-0.52) 
0.46 
(0.28-0.74) 
    
 
 
 
Table 3.3 Legend: Crude and adjusted odds ratios for patients to present with a SBP   
                               >160mmHg over all study years. 
* Controlling for  all variables with a P<0.20  
01995 is the referent year for all regression analyses 
$ 95% confidence intervals 
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CHAPTER IV 
 
DISCUSSION 
 
 
In the present study we compared the frequency with which patients with AHF 
presented to the hospital with SBP’s greater than 160 mmHg in four separate cohorts 
studied  between 1995 and 2011-13. The rationale for studying how often these patients 
present is based on the fact that presenting SBP has been demonstrated to be clinically 
useful as a guide to help clinicians make decisions regarding the early diagnostic and 
treatment approach they will pursue in patients presenting with suspected AHF. Clinical 
experience and recent unpublished data suggested that there may be fewer of these 
hypertensive patients with AHF than in the past. Our results demonstrate that there has 
been a significant decrease in the percentage of AHF patients with SBP > 160 mmHg 
over time at the time of hospital presentation as well as a similar decrease in the mean 
SBP at presentation.  
Despite a decrease the proportion of patients with an SBP> 160 mmHg over 
time, the overall mean SBP results we observed in the study cohorts are consistent with 
other large observational studies of patients admitted with AHF. The Acute 
Decompensated Heart Failure National Registry (ADHERE) collected data on patients 
with AHF who were admitted to 263 medical centers from all regions of the United 
States. An early study from ADHERE of patients admitted between 2001 and 2003 
found that mean SBP on presentation was 144 mmHg which falls between our mean 
SBP’s for 2000 and 2006 which were 147 mmHg and 141 mmHg respectively.26 
Similarly the Organized Program to Initiate Lifesaving Treatment in Hospitalized 
Patients with Heart Failure (OPTIMIZE-HF) national registry  study found that the mean 
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SBP of patient admitted with AHF in 2003 and 2004 was 143 mmHg. This suggests that 
despite the redistribution of SBP into lower SBP strata there remains a large group of 
patients with normal to elevated SBP at the time of presentation. 
The importance of SBP in providing a framework for clinicians to approach 
patients with AHF has been discussed in several prior studies. 5-7 The Optimize-HF 
registry contained nearly 50,000 patients and found that those patients with higher 
SBP’s were more likely to be female, African American, and to have HF with a 
preserved ejection fraction. 4 It is because of this relationship between SBP and the 
characteristics of patients with AHF that SBP is felt to be useful in the ED or acute care 
setting.  The Optimize-HF registry   also documented the relationship between initial or 
triage SBP and short-term (inpatient) and post-discharge prognosis, where patients 
having higher SBPs (> 140mmHg) were found to have a decreased mortality compared 
with patients in lower SBP strata.  4 It is currently unknown what the effect on short and 
longer-term prognosis might be, if any, if the proportion of patients with AHF who have 
elevated SBP is declining.    Lastly, an AHA working group focused specifically on AHF 
in the ED has advocated an approach whereby SBP is central  to early risk stratification 
with patients having an SBP>160 falling into the lowest risk group and having the best 
inhospital and post-discharge prognosis. 27   However, if the distribution of SBPs is 
evolving over time this approach may need to be refined as it may be more difficult 
presently to distinguish between which patients will have a better or worse prognosis.  
Prior literature has described  patients with AHF and significantly elevated SBP as 
having  “vascular failure” rather than “cardiac failure”. This distinction may be helpful to 
clinicians as they attempt to distinguish between patients with different treatment needs. 
6, 7, 28 The vascular failure patient typically does not have significant total body fluid 
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overload and, as a result, early treatment needs to focus on afterload reduction rather 
than   intensive diuresis. 6, 28    However, if elevated SBP is becoming less common than 
in the past, it may become more difficult to clinically  distinguish between vascular and 
cardiac failure patients.  
It is unclear why presenting SBP, and the frequency of AHF accompanied by 
SBP> 160mmHg, has decreased over time, but it is known, and our data demonstrates, 
that many demographic and clinical features of patients with AHF have changed during 
the last few decades. For instance, a large study of more than 55 million Medicare 
patients    admitted and subsequently discharged with a principle diagnosis of AHF 
found that admission rates for AHF declined significantly between 1998 and 2008 
perhaps reflecting improved management of these patients. 3  Findings  from the WHFS 
have demonstrated that, since 1995, patients admitted with AHF have become older, 
have a greater comorbid disease burden, but have an improved post-discharge 
prognosis.8, 29 Similarly, other studies have documented improvement in the long-term  
survival of AHF patients over the last several years.30, 31 With increased survival, 
particularly of HF patients with reduced EF, the overall mix of patients presenting with  
AHF (incident and recurrent) would be expected to change as well, which would in turn 
be expected to lower the mean SBP’s at the time of acute presentation if more patients 
with recurrent AHF are present. 
Other factors may explain why there may be fewer  patients with elevated BP 
and AHF presenting for treatment   than in the past.  First, the outpatient management 
of HF has changed significantly since 1995, 32-35 and there has been an enhanced 
recognition that the outpatient treatment of hypertension in patients with HF can 
decrease the incidence of AHF presentations. 36-38 Indeed in our sample there was a 
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steady increase in the use of ACE-inhibitors and beta-blockers in isolation and in 
combination in the outpatient management of these patients over time. Others have 
documented similar increases in beta blocker and ACE-inhibitor use between 1995 and 
2000. 39 It is unclear how the outpatient pharmacologic management of patients with HF 
influences the SBP when a patient presents with AHF, but it may, in part ,explain the 
trends we have observed.  
Furthermore, the management of hypertension has changed significantly over 
time with new definitions of hypertension and targets for therapy being put forth with 
each Joint National Committee on the Detection, Evaluation, and Treatment of High 
Blood Pressure (JNC) update since 1977 (most recent update is JNC-8). 10-12, 40  Of 
note, in the present study we observed a significant increase in the proportion of 
patients with preexisting hypertension over time which likely  reflects the increased 
comorbid disease burden in these patients as well as the changing definitions of what 
constitutes hypertension and the heightened focus on this disease. Since  hypertension 
is an important cause of HF, and blood pressure control has improved somewhat over 
time, these changing trends  may have also influenced our results. 41, 42 
 
D.  Study Strengths and Limitations 
The major strength of this study lies in its’ ability to combine detailed current and 
historical data in order to better understand how patients with AHF may have changed 
their  presentation, specifically with regards to SBP,  over time. . However, there are 
also several limitations that need to be acknowledged in the interpretation of these 
study findings. First there was no standard way in which initial SBP was measured 
clinically.  Next, ejection fraction (EF) is an important variable that is related to 
presenting SBP insofar as patients with hypertensive AHF presentations often have 
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preserved EF.  However, data on EF was missing in a large proportion of the patients in 
our study sample and was not included in our regression models. Similarly, BNP was 
not obtained in the first 2 patient  cohorts due to it not being used at all the study 
medical centers.   Another potential limitation is that WHFS data were compared to an 
ED-based AHF study and there were some differences in how the patients were 
identified (chart identification versus warm pursuit surveillance). Such heterogeneity 
could introduce a potential selection bias. However, the significant trend in reduction of 
hypertensive presentations in patients with AHF was also observed in the most recent 
WHFS cohort (2006), reinforcing the likelihood of our observed trends being real.  
Changes in prehospital (EMS) treatment may also have influenced the initial SBP’s,  but 
the proportion of patients transported by EMS has not significantly changed over time 
(data not shown). This study was also based on data collected from hospitals in central 
MA which  may  narrow  the generalizability of the present findings. This limitation is 
tempered by the fact that the sociodemographic characteristics of the greater Worcester 
population are similar to those observed in the general U.S. population.   
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CHAPTER V 
 
CONCLUSIONS 
 
Our study demonstrates that the proportion of patients with AHF with SBP >160 
mmHg at the time of presentation to the hospital has significantly declined over time. In 
addition, the mean SBP at presentation has also declined during the more than decade 
long period covered under this study. One clinical consequence of these declines is that 
it may make it more difficult to distinguish between vascular and cardiac failure patients 
in the ED. Why these changes have occurred is unknown but is likely a result of the 
changes that have occurred in the outpatient management of both HF and hypertension 
over the last 15-20 years. The improved management of these patients has resulted in 
patients with HF living longer and having less frequent hospitalizations. 3, 8, 30 As a 
result, the overall mix of patients presenting with AHF has evolved since our earliest 
study sample was selected. These findings may help inform clinical trials as to what the 
contemporary clinical profiles of patients presenting with signs and symptoms of  AHF 
are. It also highlights a need to study the short and long-term prognosis of these 
patients in  surveillance studies as they continue to increase in prevalence with the 
aging of the population. Multicenter data on the clinical characteristics, treatment, and 
prognosis of patients with AHF from racially diverse population over time would help to 
more systematically determine the generalizability of the trends described in this study. 
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